Thanks Stuart Peltz, Founder & CEO PTC Therapeutics for joining us! From Rutgers RWJMedSchool - to industry leader in #RNA #biology - he has guided PTC from a #research organization to a publicly-traded, global commercial organization! bit.ly/3JoTJsg $PTCT #raredisease #STEM #genetherapy

Inspiring stories like this are why we’re dedicated to researching therapies for ultra-rare diseases such as #AADC.

What is #genetherapy and what kind of promise does it hold for the future of healthcare? Discover the science behind gene therapy and how it could contribute to advancing transformative treatment options for patients living with rare genetic diseases.

We are proud to announce that we have received a positive CHMP opinion for the first #genetherapy to treat #AADCdeficiency, a rare genetic disorder.

PTC is at the forefront of #genetherapy, an exciting and transformative area. We are committed to bringing life-changing therapies to patients who have limited or no treatment options, like those living with #AADCdeficiency.

We recently issued our 2021 Corporate Sustainability Report, outlining our efforts and impact in five key areas: our patients, our people, our community, our values, and our environment. Read the full report: bit.ly/392pzxS

We are excited to announce that PTC’s Gene Therapy Center of Excellence in Hopewell, NJ was named a winner in the New Good Neighbor Awards by the NJBIA. Read more in NJ Business Magazine: bit.ly/3apQ8ha

The first and only treatment for #AADCdeficiency, a rare genetic disease impacting children, is now approved in Europe. Read more about this significant milestone at bit.ly/3PHitzf #AADCdeficiency #genetherapy

To honor #WorldDuchenneAwareness Day, we’re highlighting and celebrating inspiring women in the Duchenne community. Read their incredible stories: bit.ly/3U1Yluf

We are thrilled to announce PTC has been selected as winner of the BioTechnology Innovator of the Year Award as part of the 2022 BioTech Breakthrough Awards Program! Congrats, #OnePTC!

PTC will provide an update on commercial progress and R&D pipeline at the 41st Annual J.P. Morgan Healthcare Conference this morning. #JPM23 Read the press release: ir.ptcbio.com/news-releases/…

Today we’ve published final draft guidance which now recommends ataluren for routine NHS funding for treating Duchenne muscular dystrophy caused by a nonsense mutation. You can read the draft guidance here: bit.ly/3iJgP4R

We're expanding access to critical mental health care through the Behavioral Healthcare Provider Loan Redemption Program. If you work as a behavioral health provider in New Jersey, you're now eligible for up to $180,000 in student loan forgiveness. hesaa.org/Pages/BHLRP.as…

Do you remember when you joined Twitter? I do! #MyTwitterAnniversary

On #LouGehrigDay, we’re honoring his legacy and raising awareness for #ALS and related #neuromuscular diseases by sharing some of our favorite MLB teams. Learn more about this #raredisease and our enrolling CARDINALS clinical trial: bit.ly/3BU6tFb

This morning, we shared positive interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington’s disease (HD) patients. Read more: ir.ptcbio.com/news-releases/… #Huntingtonsdisease

Our teammates are in Times Square this morning to ring the Nasdaq Exchange opening bell in celebration of PTC's 10th anniversary as a public company. Join our CEO Matthew B. Klein, M.D., M.S., FACS and others in the livestream beginning at 9 a.m. EDT: livestream.com/accounts/27896…

Welcoming PTC Therapeutics to the Nasdaq Exchange Opening Bell. x.com/i/broadcasts/1…

🔬 PTC Therapeutics is translating science to transform lives for patients. $PTCT is a science-driven, patient-centered biopharmaceutical company focused on discovering best-in-class treatments & commercializing medicine for patients with rare disease. #NasdaqListed

Count down to today’s stock market opening with us! CEO Matthew Klein and others were in Times Square this morning to celebrate our 25th anniversary and 10th year as a public company. Video credit: Nasdaq Exchange